A Study in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1538 participants.

Also called NCT01435616

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,538 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01435616
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Finland, Germany, Greece, Hungary, Israel, Italy, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01435616. Randomized; double masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2018-04-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Patients With Type 2 Diabetes Mellitus
Acronym
IMAGINE 2
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Glargine
Intervention (Drug)
LY2605541
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01435616
Content hash
29549e04cb6857fcdb55f060426ac85790431ebc4d573121e342c64ffe7b902d